Dehydroleucodine is primarily studied for its anti-inflammatory and gastroprotective properties. It has shown effectiveness in reducing gastric lesions caused by ethanol or stress in animal models, making it a potential candidate for treating gastric ulcers. The compound also exhibits spasmolytic activity, helping to relax smooth muscle contractions in the gastrointestinal tract, which may benefit conditions like irritable bowel syndrome.

In addition, dehydroleucodine demonstrates antimicrobial and antiparasitic activities, particularly against protozoan parasites such as Trypanosoma cruzi, the causative agent of Chagas disease. Its ability to modulate cell proliferation has led to research in oncology, where it shows cytotoxic effects on certain cancer cell lines by inducing cell cycle arrest and apoptosis.

Due to its diverse biological activities, dehydroleucodine is considered a promising lead compound for developing new drugs targeting gastrointestinal disorders, infectious diseases, and possibly cancer.